Edition:
India

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.70USD
20 Jun 2018
Change (% chg)

$0.01 (+0.59%)
Prev Close
$1.69
Open
$1.70
Day's High
$1.73
Day's Low
$1.68
Volume
226,498
Avg. Vol
182,390
52-wk High
$3.10
52-wk Low
$1.35

Chart for

About

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in... (more)

Overall

Beta: -0.51
Market Cap(Mil.): $151.63
Shares Outstanding(Mil.): 59.70
Dividend: --
Yield (%): --

Financials

BRIEF-Trevena Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S

03 May 2018

BRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In China

* TREVENA INC. AND JIANGSU NHWA PHARMACEUTICAL CO. LTD ANNOUNCE LICENSE AGREEMENT FOR OLICERIDINE IN CHINA

02 May 2018

BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018

* TREVENA SAYS ON APRIL 9, ROBERTO CUCA, CHIEF FINANCIAL OFFICER OF CO FORMALLY NOTIFIED CO OF HIS RESIGNATION, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source text: (https://bit.ly/2GVszsP) Further company coverage:

12 Apr 2018

BRIEF-Trevena Reports Q4 Loss Per Share $0.24

* COMPANY EXPECTS THAT EXPENSES WILL DECREASE IN 2018 COMPARED TO 2017

07 Mar 2018

BRIEF-Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2‍​

* TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2‍​

06 Jan 2018

BRIEF-Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection

* TREVENA ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR OLINVO (OLICERIDINE) INJECTION

03 Jan 2018

Earnings vs. Estimates